Matrix metalloproteinases as regulators of vein structure and function: Implications in chronic venous disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 355, Issue 3, 2015, Pages 410-428

  MacColl, Elisabeth ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CHYMASE; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 21; MATRIX METALLOPROTEINASE 22; MATRIX METALLOPROTEINASE 23; MATRIX METALLOPROTEINASE 24; MATRIX METALLOPROTEINASE 25; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE 27; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; PROSTANOID; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; UNCLASSIFIED DRUG; MATRIX METALLOPROTEINASE INHIBITOR;

BLOOD VESSEL FUNCTION; CALCIUM SIGNALING; CHRONIC DISEASE; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENZYME ACTIVITY; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; HUMAN; LEUKOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TISSUE STRUCTURE; VARICOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; VEIN DISEASE; VEIN FUNCTION; VEIN STRUCTURE; VENOUS PRESSURE; ANATOMY AND HISTOLOGY; ANIMAL; ENZYMOLOGY; PATHOLOGY; PHYSIOLOGY; TISSUE DISTRIBUTION; VASCULAR DISEASES; VEIN;

ANIMALS; CHRONIC DISEASE; HUMANS; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; TISSUE DISTRIBUTION; VASCULAR DISEASES; VEINS;

EID: 84966431155     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.227330     Document Type: Review

References (134)

1. Aimes RT and Quigley JP (1995) Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4-and 1/4-length fragments. J Biol Chem 270:5872-5876.
2. Aravind B, Saunders B, Navin T, Sandison A, Monaco C, Paleolog EM, and Davies AH (2010) Inhibitory effect of TIMP influences the morphology of varicose veins. Eur J Vasc Endovasc Surg 40:754-765.
3. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, Cohen C, Moses M, Kilroy S, and Arnold RS, et al. (2002) Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci USA 99:715-720.
4. Aremu MA, Mahendran B, Butcher W, Khan Z, Colgan MP, Moore DJ, Madhavan P, and Shanik DG (2004) Prospective randomized controlled trial: conventional versus powered phlebectomy. J Vasc Surg 39:88-94.
5. Asanuma K, Magid R, Johnson C, Nerem RM, and Galis ZS (2003) Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 284:H1778-H1784.
6. Aunapuu M and Arend A (2005) Histopathological changes and expression of adhesion molecules and laminin in varicose veins. Vasa 34:170-175.
7. Badauy CM, Gomes SS, Sant'Ana Filho M, and Chies JA (2007) Ehlers-Danlos syndrome (EDS) type IV: review of the literature. Clin Oral Investig 11:183-187.
8. Badier-Commander C, Couvelard A, Henin D, Verbeuren T, Michel JB, and Jacob MP (2001) Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. J Pathol 193:398-407.
9. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, and Jacob MP (2000) Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 192:105-112.
10. Baker AH, Edwards DR, and Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:3719-3727.
11. Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, and Radisky ES (2012) Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem 287:15935-15946.
12. Beebe-Dimmer JL, Pfeifer JR, Engle JS, and Schottenfeld D (2005) The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 15:175-184.
13. Benjamin MM and Khalil RA (2012) Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 103:209-279 Experientia Supplementum.
14. Bernardo MM, Brown S, Li ZH, Fridman R, and Mobashery S (2002) Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem 277:11201-11207.
15. Bode W, Fernandez-Catalan C, Grams F, Gomis-Rüth FX, Nagase H, Tschesche H, and Maskos K (1999) Insights into MMP-TIMP interactions. Ann N Y Acad Sci 878:73-91.
16. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, and Kuliopulos A (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313.
17. Cesarone MR, Belcaro G, Pellegrini L, Ledda A, Vinciguerra G, Ricci A, Di Renzo A, Ruffini I, Gizzi G, and Ippolito E, et al. (2006) Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 57:131-138.
18. Chen Q, Jin M, Yang F, Zhu J, Xiao Q, and Zhang L (2013) Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013:928315.
19. Chetty C, Bhoopathi P, Joseph P, Chittivelu S, Rao JS, and Lakka S (2006) Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 5: 2289-2299.
20. Chew DK, Conte MS, and Khalil RA (2004) Matrix metalloproteinase-specific inhibition of Ca21 entry mechanisms of vascular contraction. J Vasc Surg 40: 1001-1010.
21. Chung L, Dinakarpandian D, Yoshida N, Lauer-Fields JL, Fields GB, Visse R, and Nagase H (2004) Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J 23:3020-3030.
22. Corcos L, De Anna D, Dini M, Macchi C, Ferrari PA, and Dini S (2000) Proximal long saphenous vein valves in primary venous insufficiency. J Mal Vasc 25:27-36.
23. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264.
24. Cui Y, Sun YW, Lin HS, Su WM, Fang Y, Zhao Y, Wei XQ, Qin YH, Kohama K, and Gao Y (2014) Platelet-derived growth factor-BB induces matrix metalloproteinase-2 expression and rat vascular smooth muscle cell migration via ROCK and ERK/p38 MAPK pathways. Mol Cell Biochem 393:255-263.
25. Dang Y, Li W, Tran V, and Khalil RA (2013) EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone. Biochem Pharmacol 86:734-747.
26. Delis KT, Gloviczki P, Wennberg PW, Rooke TW, and Driscoll DJ (2007) Hemodynamic impairment, venous segmental disease, and clinical severity scoring in limbs with Klippel-Trenaunay syndrome. J Vasc Surg 45:561-567.
27. Deng DX, Spin JM, Tsalenko A, Vailaya A, Ben-Dor A, Yakhini Z, Tsao P, Bruhn L, and Quertermous T (2006) Molecular signatures determining coronary artery and saphenous vein smooth muscle cell phenotypes: distinct responses to stimuli. Arterioscler Thromb Vasc Biol 26:1058-1065.
28. Dorecka M, Francuz T, Garczorz W, Siemianowicz K, and Romaniuk W (2014) The influence of elastin degradation products, glucose and atorvastatin on metalloproteinase-1,-2,-9 and tissue inhibitor of metalloproteinases-1,-2,-3 expression in human retinal pigment epithelial cells. Acta Biochim Pol 61:265-270.
29. Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, Meissner MH, Moneta GL, Myers K, and Padberg FT, et al.; American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification (2004) Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 40:1248-1252.
30. English WR, Holtz B, Vogt G, Knäuper V, and Murphy G (2001) Characterization of the role of the "MT-loop": an eight-amino acid insertion specific to progelatinase A (MMP2) activating membrane-type matrix metalloproteinases. J Biol Chem 276: 42018-42026.
31. Félétou M and Vanhoutte PM (2006) Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol 26:1215-1225.
32. Foda HD, Rollo EE, Drews M, Conner C, Appelt K, Shalinsky DR, and Zucker S (2001) Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340). Am J Respir Cell Mol Biol 25:717-724.
33. Fu X, Kao JL, Bergt C, Kassim SY, Huq NP, d'Avignon A, Parks WC, Mecham RP, and Heinecke JW (2004) Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity: specific structural motifs control protein oxidation. J Biol Chem 279:6209-6212.
34. Gandhi RH, Irizarry E, Nackman GB, Halpern VJ, Mulcare RJ, and Tilson MD (1993) Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. J Vasc Surg 18:814-820.
35. Garcia JG, Patterson C, Bahler C, Aschner J, Hart CM, and English D (1993) Thrombin receptor activating peptides induce Ca21 mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. J Cell Physiol 156:541-549.
36. Gillespie DL, Patel A, Fileta B, Chang A, Barnes S, Flagg A, Kidwell M, Villavicencio JL, and Rich NM (2002) Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13. J Surg Res 106:233-238.
37. Gomez I, Benyahia C, Louedec L, Leséche G, Jacob MP, Longrois D, and Norel X (2014) Decreased PGE2 content reduces MMP-1 activity and consequently increases collagen density in human varicose vein. PLoS One 9:e88021.
38. Gross J and Lapiere CM (1962) Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 48:1014-1022.
39. Haviarová Z, Weismann P, Stvrtinová V, and Benuska J (1999) The determination of the collagen and elastin amount in the human varicose vein by the computer morphometric method. Gen Physiol Biophys 18 (Suppl 1):30-33.
40. Herman MP, Sukhova GK, Kisiel W, Foster D, Kehry MR, Libby P, and Schönbeck U (2001) Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 107:1117-1126.
41. Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, and Bringmann A (2007) Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci 48:4360-4367.
42. Hu J, Van den Steen PE, Sang QX, and Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:480-498.
43. Ichihara S, Noda A, Nagata K, Obata K, Xu J, Ichihara G, Oikawa S, Kawanishi S, Yamada Y, and Yokota M (2006) Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 69:726-735.
44. Jacob MP, Cazaubon M, Scemama A, Prié D, Blanchet F, Guillin MC, and Michel JB (2002) Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation 106:535-538.
45. Jacobsen JA, Major Jourden JL, Miller MT, and Cohen SM (2010) To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 1803:72-94.
46. Jawien A (2003) The influence of environmental factors in chronic venous insufficiency. Angiology 54 (Suppl 1):S19-S31.
47. Jin UH, Suh SJ, Chang HW, Son JK, Lee SH, Son KH, Chang YC, and Kim CH (2008) Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. J Cell Biochem 104:15-26.
48. Johnson AR, Pavlovsky AG, Ortwine DF, Prior F, Man CF, Bornemeier DA, Banotai CA, Mueller WT, McConnell P, and Yan C, et al. (2007) Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 282: 27781-27791.
49. Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, Delaissé JM, and Foged NT (2002) Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277:44061-44067.
50. Kim CH, Cho YS, Chun YS, Park JW, and Kim MS (2002) Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretchactivated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res 90:E25-E33.
51. Kockx MM, Knaapen MW, Bortier HE, Cromheeke KM, Boutherin-Falson O, and Finet M (1998) Vascular remodeling in varicose veins. Angiology 49:871-877.
52. Kucukguven A and Khalil RA (2013) Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets 14: 287-324.
53. Lacroix P, Aboyans V, Preux PM, Houlès MB, and Laskar M (2003) Epidemiology of venous insufficiency in an occupational population. Int Angiol 22:172-176.
54. Le Dévéhat C, Khodabandehlou T, Vimeux M, and Kempf C (1997) Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp 17 (Suppl 1):27-33.
55. Lee HY, You HJ, Won JY, Youn SW, Cho HJ, Park KW, Park WY, Seo JS, Park YB, and Walsh K, et al. (2008) Forkhead factor, FOXO3a, induces apoptosis of endothelial cells through activation of matrix metalloproteinases. Arterioscler Thromb Vasc Biol 28:302-308.
56. Lee J, Banu SK, Subbarao T, Starzinski-Powitz A, and Arosh JA (2011) Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases. Mol Cell Endocrinol 332:306-313.
57. Lee S, Lee W, Choe Y, Kim D, Na G, Im S, Kim J, Kim M, Kim J, and Cho J (2005) Gene expression profiles in varicose veins using complementary DNA microarray. Dermatol Surg 31:391-395.
58. Li J, Rush TS, 3rd, Li W, DeVincentis D, Du X, Hu Y, Thomason JR, Xiang JS, Skotnicki JS, and Tam S, et al. (2005) Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg Med Chem Lett 15:4961-4966.
59. Li PC, Pan CH, Sheu MJ, Wu CC, Ma WF, and Wu CH (2014) Deep sea water prevents balloon angioplasty-induced hyperplasia through MMP-2: an in vitro and in vivo study. PLoS One 9:e96927.
60. Lim CS and Davies AH (2009) Pathogenesis of primary varicose veins. Br J Surg 96: 1231-1242.
61. Lim CS, Kiriakidis S, Paleolog EM, and Davies AH (2012) Increased activation of the hypoxia-inducible factor pathway in varicose veins. J Vasc Surg 55: 1427-1439.
62. Lim CS, Qiao X, Reslan OM, Xia Y, Raffetto JD, Paleolog E, Davies AH, and Khalil RA (2011) Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg 53:764-773.
63. Luan Z, Chase AJ, and Newby AC (2003) Statins inhibit secretion of metalloproteinases-1,-2,-3, and-9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23:769-775.
64. Majed BH and Khalil RA (2012) Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev 64:540-582.
65. Mann MW (2011) Sclerotherapy: it is back and better. Clin Plast Surg 38:475-487, vii vii.
66. Mannello F, Medda V, Ligi D, and Raffetto JD (2013) Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol 11:354-365.
67. Manzetti S, McCulloch DR, Herington AC, and van der Spoel D (2003) Modeling of enzyme-substrate complexes for the metalloproteases MMP-3, ADAM-9 and ADAM-10. J Comput Aided Mol Des 17:551-565.
68. Mao D, Zhang Y, Lu H, and Zhang H (2014) Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment. Tumour Biol 35:8217-8223.
69. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, 2nd, Coughlin SR, and Owens GK (1993) Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 91:94-98.
70. Mekky S, Schilling RS, and Walford J (1969) Varicose veins in women cotton workers. An epidemiological study in England and Egypt. BMJ 2:591-595.
71. Meng Q, Malinovskii V, Huang W, Hu Y, Chung L, Nagase H, Bode W, Maskos K, and Brew K (1999) Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P19 residue of substrate. J Biol Chem 274: 10184-10189.
72. Merchant RF, Pichot O, and Myers KA (2005) Four-year follow-up on endovascular radiofrequency obliteration of great saphenous reflux. Dermatol Surg 31:129-134.
73. Milkiewicz M, Doyle JL, Fudalewski T, Ispanovic E, Aghasi M, and Haas TL (2007) HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shearstress-induced angiogenesis in rat skeletal muscle. J Physiol 583:753-766.
74. Min RJ, Khilnani N, and Zimmet SE (2003) Endovenous laser treatment of saphenous vein reflux: long-term results. J Vasc Interv Radiol 14:991-996.
75. Misra S, Fu AA, Rajan DK, Juncos LA, McKusick MA, Bjarnason H, and Mukhopadhyay D (2008) Expression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and-9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. J Vasc Interv Radiol 19:252-259.
76. Morla AO and Mogford JE (2000) Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion kinase. Biochem Biophys Res Commun 272:298-302.
77. Nagase H, Visse R, and Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562-573.
78. Naoum JJ, Hunter GC, Woodside KJ, and Chen C (2007) Current advances in the pathogenesis of varicose veins. J Surg Res 141:311-316.
79. Ng MY, Andrew T, Spector TD, and Jeffery S; Lymphoedema Consortium (2005) Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs. J Med Genet 42:235-239.
80. Norgauer J, Hildenbrand T, Idzko M, Panther E, Bandemir E, Hartmann M, Vanscheidt W, and Herouy Y (2002) Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 147:1180-1186.
81. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, and Alexander DB, et al. (2001) The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107:789-800.
82. Olson MW, Toth M, Gervasi DC, Sado Y, Ninomiya Y, and Fridman R (1998) High affinity binding of latent matrix metalloproteinase-9 to the alpha2(IV) chain of collagen IV. J Biol Chem 273:10672-10681.
83. Ono T, Bergan JJ, Schmid-Schönbein GW, and Takase S (1998) Monocyte infiltration into venous valves. J Vasc Surg 27:158-166.
84. Park HI, Jin Y, Hurst DR, Monroe CA, Lee S, Schwartz MA, and Sang QX (2003) The intermediate S19 pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J Biol Chem 278:51646-51653.
85. Patterson ML, Atkinson SJ, Knäuper V, and Murphy G (2001) Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett 503:158-162.
86. Pei D, Kang T, and Qi H (2000) Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J Biol Chem 275:33988-33997.
87. Pei D and Weiss SJ (1995) Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375:244-247.
88. Pelmenschikov V and Siegbahn PE (2002) Catalytic mechanism of matrix metalloproteinases: two-layered ONIOM study. Inorg Chem 41:5659-5666.
89. Pochetti G, Gavuzzo E, Campestre C, Agamennone M, Tortorella P, Consalvi V, Gallina C, Hiller O, Tschesche H, and Tucker PA, et al. (2006) Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem 49:923-931.
90. Proebstle TM, Lehr HA, Kargl A, Espinola-Klein C, Rother W, Bethge S, and Knop J (2002) Endovenous treatment of the greater saphenous vein with a 940-nm diode laser: thrombotic occlusion after endoluminal thermal damage by laser-generated steam bubbles. J Vasc Surg 35:729-736.
91. Psaila JV and Melhuish J (1989) Viscoelastic properties and collagen content of the long saphenous vein in normal and varicose veins. Br J Surg 76:37-40.
92. Puerta DT, Lewis JA, and Cohen SM (2004) New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. J Am Chem Soc 126:8388-8389.
93. Raffetto JD, Barros YV, Wells AK, and Khalil RA (2010a) MMP-2 induced vein relaxation via inhibition of [Ca21]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res 159:755-764.
94. Raffetto JD and Khalil RA (2008a) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75:346-359.
95. Raffetto JD and Khalil RA (2008b) Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 23:85-98.
96. Raffetto JD and Khalil RA (2011) Ca(21)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins. J Vasc Surg 54:489-496.
97. Raffetto JD, Qiao X, Beauregard KG, and Khalil RA (2010b) Estrogen receptormediated enhancement of venous relaxation in female rat: implications in sexrelated differences in varicose veins. J Vasc Surg 51:972-981.
98. Raffetto JD, Qiao X, Koledova VV, and Khalil RA (2008) Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose veins. J Vasc Surg 48:447-456.
99. Raffetto JD, Ross RL, and Khalil RA (2007) Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K1 channels: relevance to varicose vein formation. J Vasc Surg 45:373-380.
100. Rao VH, Kansal V, Stoupa S, and Agrawal DK (2014) MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Physiol Rep 2:e00224.
101. Reagan B and Folse R (1971) Lower limb venous dynamics in normal persons and children of patients with varicose veins. Surg Gynecol Obstet 132:15-18.
102. Recek C (2006) Conception of the venous hemodynamics in the lower extremity. Angiology 57:556-563.
103. Reddy VS, Prabhu SD, Mummidi S, Valente AJ, Venkatesan B, Shanmugam P, Delafontaine P, and Chandrasekar B (2010) Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol 299:H1242-H1254.
104. Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, Kaldjian E, Welgus H, and Baragi V (2003) Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 48: 1742-1749.
105. Saiki S, Sakai K, Saiki M, Kitagawa Y, Umemori T, Murata K, Matsui M, and Hirose G (2006) Varicose veins associated with CADASIL result from a novel mutation in the Notch3 gene. Neurology 67:337-339.
106. Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT, Jr, Hobson RW, 2nd, Durán WN, and Pappas PJ (2001) Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 34:930-938.
107. Sansilvestri-Morel P, Fioretti F, Rupin A, Senni K, Fabiani JN, Godeau G, and Verbeuren TJ (2007) Comparison of extracellular matrix in skin and saphenous veins from patients with varicose veins: does the skin reflect venous matrix changes? Clin Sci (Lond) 112:229-239.
108. Sansilvestri-Morel P, Rupin A, Jullien ND, Lembrez N, Mestries-Dubois P, Fabiani JN, and Verbeuren TJ (2005) Decreased production of collagen Type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP-3. J Vasc Res 42:388-398.
109. Sato H, Kita M, and Seiki M (1993) v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 268:23460-23468.
110. Sayer GL and Smith PD (2004) Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins. Eur J Vasc Endovasc Surg 28: 479-483.
111. Schmid-Schönbein GW, Takase S, and Bergan JJ (2001) New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology 52 (Suppl 1):S27-S34.
112. Scozzafava A and Supuran CT (2000) Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 43: 3677-3687.
113. Seizer P and May AE (2013) Platelets and matrix metalloproteinases. Thromb Haemost 110:903-909.
114. Serra R, Buffone G, de Franciscis A, Mastrangelo D, Molinari V, Montemurro R, and de Franciscis S (2012) A genetic study of chronic venous insufficiency. Ann Vasc Surg 26:636-642.
115. Serra R, Gallelli L, Conti A, De Caridi G, Massara M, Spinelli F, Buffone G, Caliò FG, Amato B, and Ceglia S, et al. (2014) The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des Devel Ther 8:519-527.
116. Shi ZD, Ji XY, Berardi DE, Qazi H, and Tarbell JM (2010) Interstitial flow induces MMP-1 expression and vascular SMC migration in collagen I gels via an ERK1/2-dependent and c-Jun-mediated mechanism. Am J Physiol Heart Circ Physiol 298: H127-H135.
117. Skiles JW, Gonnella NC, and Jeng AY (2001) The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 8: 425-474.
118. Strickland DK, Ashcom JD, Williams S, Burgess WH, Migliorini M, and Argraves WS (1990) Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 265:17401-17404.
119. Suenaga N, Mori H, Itoh Y, and Seiki M (2005) CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase. Oncogene 24:859-868.
120. Takai S, Jin D, Chen H, Li W, Yamamoto H, Yamanishi K, Miyazaki M, Higashino H, Yamanishi H, and Okamura H (2014) Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats. J Hypertens 32:1637-1648, discussion 1649.
121. Takase S, Pascarella L, Bergan JJ, and Schmid-Schönbein GW (2004) Hypertensioninduced venous valve remodeling. J Vasc Surg 39:1329-1334.
122. Thodeti CK, Matthews B, Ravi A, Mammoto A, Ghosh K, Bracha AL, and Ingber DE (2009) TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling. Circ Res 104:1123-1130.
123. Turner NA, Ho S, Warburton P, O'Regan DJ, and Porter KE (2007) Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro compared with paired internal mammary artery cells. J Vasc Surg 45:1022-1028.
124. Venturi M, Bonavina L, Annoni F, Colombo L, Butera C, Peracchia A, and Mussini E (1996) Biochemical assay of collagen and elastin in the normal and varicose vein wall. J Surg Res 60:245-248.
125. Visse R and Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839.
126. Waitkus-Edwards KR, Martinez-Lemus LA, Wu X, Trzeciakowski JP, Davis MJ, Davis GE, and Meininger GA (2002) alpha(4)beta(1) Integrin activation of L-type calcium channels in vascular smooth muscle causes arteriole vasoconstriction. Circ Res 90:473-480.
127. Wojtowicz-Praga SM, Dickson RB, and Hawkins MJ (1997) Matrix metalloproteinase inhibitors. Invest New Drugs 15:61-75.
128. Woodside KJ, Hu M, Burke A, Murakami M, Pounds LL, Killewich LA, Daller JA, and Hunter GC (2003) Morphologic characteristics of varicose veins: possible role of metalloproteinases. J Vasc Surg 38:162-169.
129. Xiao Y, Huang Z, Yin H, Lin Y, and Wang S (2009) In vitro differences between smooth muscle cells derived fromvaricose veins and normal veins. J Vasc Surg 50:1149-1154.
130. Xu HM, Zhao Y, Zhang XM, Zhu T, and Fu WG (2011) Polymorphisms in MMP-9 and TIMP-2 in Chinese patients with varicose veins. J Surg Res 168:e143-e148.
131. Yin Z, Sada AA, Reslan OM, Narula N, and Khalil RA (2012) Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab 303:E55-E70.
132. Zhang H, Chalothorn D, Jackson LF, Lee DC, and Faber JE (2004) Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 95:989-997.
133. Zsotér T and Cronin RF (1966) Venous distensibility in patients with varicose veins. Can Med Assoc J 94:1293-1297.
134. Zubkova ES,Men'shikovMY, Plekhanova OS, Beloglazova IB, Ratner EI, and Parfenova EV (2014) Urokinase stimulates production of matrix metalloproteinase-9 in fibroblasts with involvement of reactive oxygen species. Bull Exp Biol Med 157:18-21.